# Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

> **NCT00006232** · PHASE3 · COMPLETED · sponsor: **West of Scotland Lymphoma Group** · enrollment: 200 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** dexamethasone
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** idarubicin
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00006232
- **Lead sponsor:** West of Scotland Lymphoma Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-10
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006232, "Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00006232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*